Beijing, China – August 1, 2024 – SineuGene, a biotechnology company focused on developing gene therapies for neurological diseases, today announced that it has secured nearly ¥100 million (approximately US$14 million) in a Pre-A round of financing. The funding was led by ZGC Capital, with participation from ZBJL Capita, Transfar Capital, and Guangzhou Sanmei Investment.

The company plans to use the funds primarily to advance the Investigational New Drug (IND) application for SNUG01, its lead product candidate targeting amyotrophic lateral sclerosis (ALS). SNUG01 is an AAV-based gene therapy designed to address a novel target for ALS. Preclinical studies have shown promising results in protecting neurons. Additionally, the company will use the funds to support the development of its other pipelines.

SineuGene has established platforms for creating gene-knockin animal models and screening AAV vectors, leveraging over a decade of research from Tsinghua University. The company is developing therapies for neurological diseases including ALS, stroke, and Parkinson's disease.

The first patient treated with SNUG01 in a compassionate use study has shown stable disease progression after one year of follow-up. Furthermore, SNUG01 is currently being investigated in an investigator initiated trial (IIT) at Peking University Third Hospital.